Locations
Company type
Result types
Industries
Employees
Founding year
The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Close
Filter
Result configuration
Continents
Select continent
Locations
Result types
Company type
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
BIORCHESTRA
Chungju-si, South Korea
A
1-10 Employees
2016
Key takeaway
BIORCHESTRA focuses on developing innovative RNA medicines and delivery systems that address significant medical needs in neurodegenerative and rare diseases of the Central Nervous System. Their best-in-class technology enhances the targeted delivery of RNA therapeutics to brain cells, offering hope for the treatment of neglected and incurable conditions.
Reference
Core business
BIORCHESTRA – Innovative RNA Therapeutics
MxT Biotech
Seoul, South Korea
A
1-10 Employees
2021
Key takeaway
The company highlights its Hydroporator® platform, which enables highly effective non-viral delivery of plasmid DNA and other genetic materials into primary cells, making it a significant player in the field of in vivo gene therapy. Their focus on microfluidic gene editing for cell therapy positions them at the forefront of innovative approaches to cancer immunotherapy and genome editing.
Reference
Core business
MxT Biotech :: Microfluidics x Therapy
We transform cancer immunotherapy, cellular engineering and genome editing with our patented non-viral genome editing technology, Hydroporator .
Femtobiomed
Seongnam-si, South Korea
A
11-50 Employees
2011
Key takeaway
FEMTOBIOMED.inc focuses on advancing targeted gene delivery through multiplexed cell therapeutics, highlighting its commitment to innovative approaches in gene therapy.
Reference
Core business
FEMTOBIOMED
Looking for more accurate results?
Find the right companies for free by entering your custom query!
25M+ companies
250M+ products
Free to use
Onegene Biotechnology
Seongnam-si, South Korea
A
- Employees
2016
Key takeaway
Onegene Biotechnology is focused on advancing research and development, particularly in multi-target drug development. Their innovative approach combines chemistry and protein engineering, which may have implications for in vivo gene therapy.
Reference
Core business
ONEGENE BIOTECHNOLOGY
Spidercore Inc.
Daejeon, South Korea
A
1-10 Employees
2020
Key takeaway
Spidercore's S.Core platform utilizes a hyper-scale AI engine to analyze nucleotide properties, aiming to enhance the development and delivery of gene therapies. Their focus on AI-driven solutions in gene-based medicine promises to improve treatment effectiveness and patient outcomes.
Reference
Core business
Spidercore Inc.
Genuv
Seoul, South Korea
A
11-50 Employees
2016
Key takeaway
Genuv is dedicated to developing treatments for neurodegenerative diseases through innovative approaches that stimulate neural stem cells and restore central nervous system (CNS) function. By targeting immune cells and utilizing phenotypic drug screening, Genuv aims to promote neuroprotection and neurogenesis, moving beyond traditional methods.
Reference
Core business
Genuv
Biopharmaceutical company. 신약발굴 플랫폼 기술을 바탕으로 퇴행성 뇌질환, 면역질환, 암질환 등, 난치성 질환분야에서 치료제를 개발하는 연구 중심 신약 개발 기업.
GENECAST
Seoul, South Korea
A
11-50 Employees
2016
Key takeaway
GENECAST is a company that specializes in liquid biopsy for early cancer detection, highlighting their innovative ADPS™ technology, which boasts a remarkable sensitivity of 0.001%. This enhanced detection capability significantly improves cancer management and treatment options.
Reference
Core business
Liquid Biopsy for Cancer Diagnosis - GENECAST
GENECAST specializes in Liquid Biopsy for early detection in Cancer Diagnosis. We have developed ADPS™, a Technology with 0.001% sensitivity ✓ Contact Us.
GC Genome
Yongin-si, South Korea
A
251-500 Employees
2013
Key takeaway
GC Genome Corporation offers a comprehensive portfolio of clinical genetic testing solutions, which may include innovative approaches relevant to in vivo gene therapy. Their focus on precision oncology and unmet medical needs highlights their commitment to advancing genetic therapies.
Reference
Core business
GC Genome | Clinical Genetic Testing | South Korea
GC Genome | Clinical Genetic Testing | NIPT | Newborn Screening | Cancer Panel | Precision Oncology | Health Checkup
Cellgentek co. ltd.
Cheongju-si, South Korea
A
11-50 Employees
-
Key takeaway
Cellgentek specializes in developing advanced In Vivo Imaging Systems, which may be relevant for applications in gene therapy. Their focus on practicality and cost-efficiency in bioimaging instruments highlights their commitment to innovative solutions in the field.
Reference
Product
Bioimaing | Products | CELLGENTEK
ELLGENTEK is a company that conducts studies and invents to create the most optimal In Vivo Imaging System. CELLGENTEK aims at the practicality of bioimaging instrument and the cost-efficiency at the same time.
Insilicogen
Yongin-si, South Korea
A
11-50 Employees
2005
Key takeaway
Insilicogen has a strong focus on bioinformatics and big data, which could be integral in enhancing the effectiveness of in vivo gene therapy through advanced data analysis and modeling techniques.
Reference
Product
Solution | Insilicogen, Inc.
New Era for Bioinformatics
Technologies which have been searched by others and may be interesting for you:
The In Vivo Gene Therapy industry in South Korea is characterized by several key considerations. Regulatory frameworks are crucial, as the Ministry of Food and Drug Safety (MFDS) oversees the approval process for gene therapies, ensuring they meet safety and efficacy standards. This regulatory environment can be both a challenge and an opportunity, as companies must navigate stringent requirements while also benefiting from government support for biotechnology initiatives. The competitive landscape is rapidly evolving, with both established firms and startups vying for market share. South Korea's advanced research infrastructure and strong investment in biotechnology provide a fertile ground for innovation. However, challenges such as high development costs and the need for extensive clinical trials can pose significant hurdles. Environmental concerns also play a role, particularly regarding the long-term effects of gene therapies and their impact on ecosystems. Global market relevance is another important aspect; South Korea aims to position itself as a leader in biopharmaceuticals, tapping into the growing global demand for gene therapies. Overall, those researching companies in this field should focus on understanding the regulatory landscape, competitive dynamics, and the broader market trends that influence the In Vivo Gene Therapy sector in South Korea.
Some interesting numbers and facts about your company results for In Vivo Gene Therapy
| Country with most fitting companies | South Korea |
| Amount of fitting manufacturers | 23 |
| Amount of suitable service providers | 8 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 2005 |
| Youngest suiting company | 2021 |
Some interesting questions that has been asked about the results you have just received for In Vivo Gene Therapy
What are related technologies to In Vivo Gene Therapy?
Based on our calculations related technologies to In Vivo Gene Therapy are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Who are Start-Ups in the field of In Vivo Gene Therapy?
Start-Ups who are working in In Vivo Gene Therapy are MxT Biotech
Which industries are mostly working on In Vivo Gene Therapy?
The most represented industries which are working in In Vivo Gene Therapy are Biotechnology, Other, Medical, IT, Software and Services, Pharmaceuticals
How does ensun find these In Vivo Gene Therapy Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.